Vertex exchanges telaprevir milestones for one-time pay-out
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals of the US has confirmed that it will receive $155 million in cash from two complicated financial transactions involving its hepatitis C virus (HCV) protease inhibitor telaprevir.